Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.
Journal: Journal of Crohn's & colitis
Published: November 19, 2025
The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study.
Journal: Journal of medical economics
Published: July 05, 2024
Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn's Disease in the United States and Europe.
Journal: Crohn's & colitis 360
Published: March 01, 2024
Validating the Simplified Endoscopic Mucosal Assessment for Crohn's Disease: A Novel Method for Assessing Disease Activity.
Journal: Inflammatory bowel diseases
Published: April 11, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Journal: Lancet (London, England)
Published: November 03, 2021
Gastrointestinal Signs and Symptoms Related to Inflammatory Bowel Disease in Patients With Moderate-to-Severe Psoriasis
Journal: Journal of drugs in dermatology : JDD
Published: December 27, 2018
Showing 1-6 of 6
Last Updated: 09/26/2026